This article is a sample from the DealForma Quarterly Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for deals involving R&D and commercialization, therapeutic areas, asset stages at signing, and deal payment terms. From there, we exported the data to Excel and used pivot tables and charts to do the rest. All data are based on publicly disclosed figures. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Partnering is the lifeblood of biopharma and 2019 started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals, according to DealForma’s extensive deals database. The strong deal trend followed a solid fourth quarter in 2018 when R&D partnering deal values hit $33 billion in close to 324 deals.
Total upfront cash and equity that flowed to the licensor in deals struck in Q1 2019 also remained in line with Q1 2018 values, to close the first quarter at $3.9 billion with another $1 billion in deals announced in just the first two weeks of Q2 2019. The 2018 numbers were buoyed by a strong fourth quarter when nine deals alone brought in $2.3 billion in upfront cash and equity.
The first quarter of 2019 comes off a strong 2018 for R&D biopharma partnering when total disclosed deal values soared to $97.9 billion, a 40 percent increase over 2017, while total upfront cash and equity hit a record $11.2 billion. The record numbers were part of an upward trend over the past five years when in 2013 total disclosed deal values were just $27.1 billion in 830 partnerships. The number of signed R&D partnerships rose to 1,071 in 2018, a 28 percent increase from the 837 deals signed in 2017.
Top 10 R&D Deals in Q1 2019 by Total Deal Value
First quarter 2019 numbers were heavily weighted by a handful of megadeals. The top ten deals in Q1 2019 by total deal value crossed $24.4 billion, or 64 percent of the all partnering deal values for the quarter.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
Specifically for Biotech, Pharma, Device, and Diagnostics
Top 5 R&D Deals in Q1 2019 by Total Upfront Cash and Equity
The list changes slightly when sorted by total upfront cash and equity payments:
Still while a handful of deals contributed the bulk of money exchanging hands, a better marker that assets are commanding higher values is the change in the median upfront cash and equity payments, which shot up to $30 million in Q1 2019, compared to an average of $13 million over the previous 11 years.
By now, everyone in this industry knows that total deal values are comprised of upfront cash and equity, back end development and sales milestones, and royalties if the deal leads to a commercialized product (i.e., the deal benchmarks for deal comps). Sometimes these values are referred to as “biobucks” because most of the total deal value is realized on the back-end reaching specific development and sales milestones. As the median upfront payments show, the actual money exchanging hands is just a tiny fraction of the potential value of the deal. In the risk-averse days of 2008-2011, many deals were back-loaded with a significant portion of “biobucks” dependent on achievement of sales targets. As Big Pharma began externalizing its R&D, they have moved toward more risk-sharing deals, and thus larger upfront payments to access technologies of interest.
The $100 Million Plus Club
What happens if we take the universe of deals where a partner shells out $100 million or more in upfront cash and equity to seal a deal?
Looking at this subset of deals, there was a sharp increase in 2018 in the number of deals where the partner/licensee shelled out $100 million or more upfront in cash and equity to seal a deal, compared to 2017. This trend continued into Q1 2019 with 10 such deals totaling $2.9 billion in upfront cash and equity payments, plus 2 more deals in just the first 2 weeks of Q2 to bring the total year-to-date total to $3.8 billion.
Deals by Stage at Signing
Earlier stage deals continue to predominate, a trend that has continued since 2014. More than 65 percent of therapeutics deals were signed at platform / discovery and preclinical stages, while deals for approved products rose back to 14 percent.
This trend really took off for deals in the $100M-plus club in 2018 as the spread of stage at signing is more evenly spread out over the past ten years.
Top Therapeutic Areas for Deals
Cancer targets remain the top therapeutic area for dealmaking with significant annual increases and more than $26 billion in upfront cash and equity paid out since 2008. Neurologic disorders are the second most prevalent therapeutic area for R&D biopharma partnering. This trend is also evident among deals in the $100 Million Plus Club.
These trends have continued into 2019 as companies focus on immunotherapies and cell and gene therapies. Recently signed megadeals in these categories include Roche’s Genentech signing a $2.3 billion partnership with Adaptive Biotechnologies to develop off-the shelf T cell therapies for a range of cancers using Adaptive’s platform. The deal came with an upfront payment of $300 million.
At the end of January, Neurocrine Biosciences paid Voyager Therapeutics $165 million in upfront and equity payments for a license to four of its mid-stage neurology gene therapy programs; and Janssen Pharmaceutical paid MeiraGTx Holdings $100 million up front to gain access to its early stage gene therapy targeting X-linked retinitis pigmentosa.
Another large immune-oncology deal, valued at $4.2 billion, was struck between GlaxoSmithKline and Merck KGaA wherein GSK paid Merck $346.6 million up front for rights to a bifunctional fusion protein targeting PD-L1 for various cancers.
But the largest deal in Q1 2019 went to AstraZeneca, which shelled out $1.35 billion in an upfront payment to Japanese pharmaceutical Daiichi Sankyo in a partnership to jointly develop and commercialize Daiichi’s antibody-drug conjugates, the most advanced being an ADC for which Daiichi expects to submit a BLA for approval to treat HER2-positive metastatic breast cancer previously treated with Genentech/Roche’s Kadcyla. It is also in several other late-stage trials for various indications. The collaboration has a total deal value of $6.9 billion if all milestones are achieved.
Marie Daghlian is a freelance writer and editor who reports on the business of biotechnology and healthcare technologies and on rare diseases for Global Gene’s Rare Daily. She also covers the industry for Big4Bio, a daily newsletter focused on the four major biotech centers in the United States.
More Research by DealForma
December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments
The top deal upfront for December 2021 was the Foghorn – Loxo (Eli Lilly) partnership for Foghorn’s Gene Traffic Control platform. Foghorn will receive $300M up front, a $80M upfront equity investment, and up to $1.3B in potential milestones, plus a US cost/profit split and ex-US royalties.
November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline
The top deal upfront for November 2021 was the Owkin – Sanofi artificial intelligence and federated learning platform research partnership to advance Sanofi’s oncology pipeline. Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.
The top deal upfront for October 2021 was the Xencor – Janssen deal for plamotamab and XmAb bispecific antibodies and new XmAb B-cell targeting bispecific antibodies for CD20-expressing hematologic malignancies. Xencor will receive $100M in upfront cash, $25M in an upfront equity investment, and is eligible for up to $1.18B in dev., reg., and sales milestones, plus tiered mid-teens to low-twenties royalties.
The top deal upfront for September 2021 was the REGENXBIO – AbbVie deal for RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases. REGENXBIO will receive $370M up front and is eligible for up to $1.38B in milestones, plus tiered royalties on net sales of RGX-314 outside the US and 50% of profits in the US.
August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors
The top deal upfront for August 2021 was the RemeGen – Seagen deal for HER2-targeted ADC disitamab vedotin for solid tumors. RemeGen will receive $200M in cash up front and is eligible to receive up to $2.4 billion in milestones, plus tiered, high single-digit to mid-teen royalties.
Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer
The top biopharma deal upfront for July 2021 was Arvinas and Pfizer’s partnership for PROTAC protein degrader ARV-471 ER+/HER2- breast cancer. Arvinas will receive $650M in cash up front, $350M in an equity investment, and is eligible to receive up to $1.4 billion in milestones, plus a 50% cost and profit split.
The top biopharma deal upfront for June 2021 was iTeos and GSK’s partnership for anti-TIGIT mAb EOS-448. iTeos will receive $625M up front, up to $1.45B in milestones, a U.S. profit split and ex-U.S. tiered royalties.
Top Biopharma Deal May 2021: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer
The top biopharma deal upfront for May 2021 was Agenus and BMS’ partnership for anti-TIGIT mAb AGEN-1777. Agenus will receive $200M up front.
Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
CRISPR Therapeutics and Vertex Pharmaceuticals amended their 2015 deal to develop and commercialize gene editing therapies. This expansion is for Phase I/II CTX001 for severe sickle cell diseases and transfusion-dependent beta-thalassemia. CRISPR will receive $900M up front, up to $200M in milestones upon the first regulatory approval, and a cost/profit split of 40%.
Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant in Phase III for advanced squamous cell carcinoma of the head and neck. Debiopharm will receive EUR188M ($227M) up front and is eligible for up to EUR710M ($856M) in milestones, plus royalties. This was the largest upfront cash and equity for a partnership signed in March 2021.
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.